{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:27:25Z","timestamp":1794547645266,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001259","name":"National Kidney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.eclinm.2025.103465","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T17:32:21Z","timestamp":1756488741000},"page":"103465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-6011","authenticated-orcid":false,"given":"Rod S.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Buyse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Ciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Detournay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Juli\u00e1n Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smeeta","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Trapero-Bertran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A.","family":"Inker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103465_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jclinepi.2023.06.013","article-title":"Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping review","volume":"160","author":"Manyara","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2025.103465_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.eclinm.2025.103465_bib3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103465_bib4","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","article-title":"Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD research programme","volume":"40","author":"Jha","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.eclinm.2025.103465_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3284","article-title":"Assessment of clinical trials supporting US Food and Drug Administration approval of novel therapeutic agents, 1995-2017","volume":"3","author":"Zhang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2025.103465_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102283","article-title":"A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials","volume":"65","author":"Ciani","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2025.103465_bib7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41581-023-00748-3","article-title":"GFR slope as a surrogate marker for future kidney failure","volume":"19","author":"Lees","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.eclinm.2025.103465_bib8","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2025.103465_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"10.1016\/j.eclinm.2025.103465_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0266462309090321","article-title":"History of HTA: introduction","volume":"25","author":"Banta","year":"2009","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.eclinm.2025.103465_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0272989X21994553","article-title":"Validity of surrogate endpoints and their impact on coverage recommendations: a retrospective analysis across international Health Technology Assessment agencies","volume":"4","author":"Ciani","year":"2021","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.eclinm.2025.103465_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2020","journal-title":"Biostatistics"},{"key":"10.1016\/j.eclinm.2025.103465_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13080","article-title":"The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports","volume":"13","author":"Taylor","year":"2009","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.eclinm.2025.103465_bib14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrd.2016.81","article-title":"Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework","volume":"15","author":"Ciani","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.eclinm.2025.103465_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","article-title":"Time to review the role of surrogate end points in health policy: state of the art and the way forward","volume":"20","author":"Ciani","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.eclinm.2025.103465_bib16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/pst.2219","article-title":"Informed decision-making: statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments","volume":"21","author":"Weir","year":"2022","journal-title":"Pharm Stat"},{"key":"10.1016\/j.eclinm.2025.103465_bib17","series-title":"NICE DSU technical support document 20: multivariate meta-analysis of summary data for combining treatment effects on correlated outcomes and evaluating surrogate endpoints","author":"Bujkiewicz","year":"2019"},{"key":"10.1016\/j.eclinm.2025.103465_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/0272989X241295665","article-title":"Multi-indication evidence synthesis in oncology health technology assessment: meta-analysis methods and their application to a case study of Bevacizumab","volume":"45","author":"Singh","year":"2025","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.eclinm.2025.103465_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz002","article-title":"A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses","volume":"3","author":"Xie","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.eclinm.2025.103465_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pst.207","article-title":"Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation","volume":"5","author":"Burzykowski","year":"2006","journal-title":"Pharm Stat"},{"key":"10.1016\/j.eclinm.2025.103465_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111389","article-title":"Low-density lipoprotein cholesterol is not a successful surrogate endpoint: author\u2019s reply","volume":"171","author":"Christensen","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2025.103465_bib23","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1001\/jama.2024.4175","article-title":"Associations between surrogate markers and clinical outcomes for nononcologic chronic disease treatments","volume":"331","author":"Wallach","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103465_bib24","series-title":"Qualification opinion for GFR slope as a surrogate endpoint in RCT for CKD","year":"2023"},{"key":"10.1016\/j.eclinm.2025.103465_bib25","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jval.2021.06.013","article-title":"Coverage and pricing recommendations of the French National Health Authority for innovative drugs: a retrospective analysis from 2014 to 2020","volume":"24","author":"Kergall","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.eclinm.2025.103465_bib26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40273-018-0742-2","article-title":"Determining value in health technology assessment: stay the course or tack away?","volume":"37","author":"Caro","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.eclinm.2025.103465_bib27","series-title":"Surrogate endpoints in cost-effectiveness analysis for use in health technology assessment","year":"2025"},{"key":"10.1016\/j.eclinm.2025.103465_bib30","series-title":"Dossier of the joint clinical assessment of a medicinal product","year":"2024"},{"key":"10.1016\/j.eclinm.2025.103465_bib28","series-title":"EUnetHTA21. D4.4 \u2013 Outcomes (Endpoints)","year":"2023"},{"key":"10.1016\/j.eclinm.2025.103465_bib29","series-title":"General methods version 7.0","year":"2023"},{"key":"10.1016\/j.eclinm.2025.103465_bib32","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data","volume":"30","author":"Grams","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.eclinm.2025.103465_bib33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2021070948","article-title":"Acute treatment effects on GFR in randomized clinical trials of kidney disease progression","volume":"33","author":"Neuen","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.eclinm.2025.103465_bib34","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1002\/sim.8282","article-title":"Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease","volume":"38","author":"Vonesh","year":"2019","journal-title":"Stats Med"},{"key":"10.1016\/j.eclinm.2025.103465_bib35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2215\/CJN.0000000000000050","article-title":"Evaluation of variation in the performance of GFR slope as a surrogate end point for kidney failure in clinical trials that differ by severity of CKD","volume":"18","author":"Collier","year":"2023","journal-title":"Clin J Amer Soc Nephrol"},{"key":"10.1016\/j.eclinm.2025.103465_bib41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103465_bib36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2025.103465_bib37","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2025.103465_bib42","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103465_bib38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.ajkd.2019.08.007","article-title":"Change in estimated GFR and albuminuria as end points in clinical trials: a viewpoint from the FDA","volume":"75","author":"Thompson","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.eclinm.2025.103465_bib39","series-title":"PARASOL: proteinuria as clinical trial endpoints in focal segmental glomerulosclersosis","year":"2024"},{"key":"10.1016\/j.eclinm.2025.103465_bib40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1681\/ASN.0000000000000117","article-title":"Change in albuminuria and GFR slope as joint surrogate end points for kidney failure: implications for phase 2 clinical trials in CKD","volume":"34","author":"Heerspink","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.eclinm.2025.103465_bib43","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2215\/CJN.03790322","article-title":"Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD","volume":"17","author":"McEwan","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.eclinm.2025.103465_bib44","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/13696998.2024.2357041","article-title":"Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom","volume":"27","author":"Ramos","year":"2024","journal-title":"J Med Econ"},{"key":"10.1016\/j.eclinm.2025.103465_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.942230","article-title":"A systematic review of the early dialogue frameworks used within health technology assessment and their actual adoption from HTA agencies","volume":"10","author":"Ibargoyen-Roteta","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.eclinm.2025.103465_bib46","series-title":"Users\u2019 guides to the medical literature: a manual for evidence-based clinical practice, surrogate outcomes","year":"2015"},{"key":"10.1016\/j.eclinm.2025.103465_bib47","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1186\/s13063-022-06904-7","article-title":"Surrogate endpoints in trials: a call for better reporting","volume":"23","author":"Ciani","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.eclinm.2025.103465_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c3653","article-title":"Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study","volume":"341","author":"la Cour","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2025.103465_bib49","article-title":"Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration","volume":"386","author":"Manyara","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2025.103465_bib50","article-title":"Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration","volume":"386","author":"Manyara","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2025.103465_bib51","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s13063-015-1038-x","article-title":"The COMET initiative database: progress and activities update","volume":"16","author":"Gargon","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.eclinm.2025.103465_bib52","series-title":"Patient and public involvement in NIHR research 2006-2019: policy intentions, progress and themes","author":"Russell","year":"2019"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:05:10Z","timestamp":1794546310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025003979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":50,"alternative-id":["S2589537025003979"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103465","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103465"}}